CHINA SECURITIES REGULATORY COMMISSION

Securities / Derivatives

Dalian Exchange Approved to Launch First Monthly Average Price Futures

By Editors | 28/07/2025

The new cash-settled contracts for key plastics aim to provide more precise hedging tools for a widely used industry pricing method.

Securities / Derivatives

China Issues Rules for Hainan Cross-Border Asset Management Pilot

By Manesh Samtani | 23/07/2025

New implementation rules allow foreign individuals and institutions to buy onshore products via Hainan, a key step in opening up the free trade port.

Securities / Derivatives

China Issues New Accounting Guidance to Curb Financial Fraud

By Editors | 19/07/2025

The CSRC has clarified eight complex accounting issues, including for convertible bonds and credit insurance, to improve disclosure quality.

Securities / Derivatives

Shanghai Exchange Launches ‘Growth Tier’ for Unprofitable Tech Firms

By Editors | 16/07/2025

New STAR Market tier for pre-profit tech companies goes live with 32 firms, featuring distinct delisting rules and enhanced investor risk warnings.

ESG / Sustainability

China Extends Green Finance Project Catalogue to Cover Loans

By Editors | 16/07/2025

The updated green finance catalogue unifies project standards for loans and bonds, expanding its scope to cover new industries.

Securities / Derivatives

China Extends Programmatic Trading Reporting Rules to Foreign Investors

By Manesh Samtani | 14/07/2025

New rules from Shanghai and Shenzhen exchanges will require international investors using the Stock Connect scheme to report their algorithmic trading activities from January 2026.

Securities / Derivatives

Dalian Exchange Launches Benzene Futures and Options

By Editors | 09/07/2025

The new derivatives aim to provide risk management tools for the world's largest aromatics producer and enhance China's pricing influence.

Securities / Derivatives

China Mandates Stricter ETF Risk Controls for Fund Managers, Brokers

By Editors | 08/07/2025

New rules require fund managers to enhance operational controls and brokers to monitor high-risk client trading, amid rapid market growth.

Securities / Derivatives

Shanghai STAR Market Approves First Unprofitable IPO Under Revived Rules

By Editors | 04/07/2025

Wuhan-based drugmaker Healthgen Biotechnology got the approval, signalling renewed policy support for innovative, pre-revenue technology and life sciences firms.